Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Equity Ratio (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Equity Ratio for 11 consecutive years, with 0.43 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 2623.82% to 0.43 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.43 through Dec 2025, down 2623.82% year-over-year, with the annual reading at 0.43 for FY2025, 2623.82% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.43 at Cartesian Therapeutics, down from 0.1 in the prior quarter.
  • The five-year high for Equity Ratio was 0.57 in Q3 2023, with the low at 1.44 in Q4 2023.
  • Average Equity Ratio over 5 years is 0.03, with a median of 0.01 recorded in 2025.
  • The sharpest move saw Equity Ratio skyrocketed 2137.2% in 2022, then plummeted 5923.46% in 2025.
  • Over 5 years, Equity Ratio stood at 0.14 in 2021, then skyrocketed by 301.55% to 0.57 in 2022, then plummeted by 355.12% to 1.44 in 2023, then soared by 98.92% to 0.02 in 2024, then plummeted by 2623.82% to 0.43 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.43, 0.1, and 0.01 for Q4 2025, Q3 2025, and Q2 2025 respectively.